In the United States, breast cancer is the most common female cancer and the second most common cause of cancer death in women.
1 Amplification or overexpression of the human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu) oncogene is present in approximately 20% to 25% of primary invasive breast cancers.
2 Trastuzumab has demonstrated a significant improvement in outcomes of women with early-stage breast cancer in key adjuvant trials, but most of these trials contained an anthracycline-based therapy followed by trastuzumab with or without a taxane in women with either node-positive or node-negative, high-risk breast cancer (usually defined as tumor size >1 cm or >2 cm).
3-8 However, several studies from the pretrastuzumab era suggest a higher risk of recurrence for patients with ERBB2-positive, node-negative tumors compared with those with ERBB2-negative tumors of the same size.
9-11 Recent retrospective studies have demonstrated a benefit from the combination of chemotherapy and trastuzumab in those with node-negative breast cancer and a time trend increase in the use of these agents.
12-14